These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 32298020)

  • 21. [Comparison of Plerixafor or Cyclophosphamide Combined with G-CSF in Mobilization of Peripheral Blood Stem Cells in Multiple Myeloma].
    Li WT; Ma LM; Lian Y; Wang QG; Gao ZJ; Zhao S
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Oct; 31(5):1403-1409. PubMed ID: 37846691
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low-Dose Cyclophosphamide versus Intermediate-High-Dose Cyclophosphamide versus Granulocyte Colony-Stimulating Factor Alone for Stem Cell Mobilization in Multiple Myeloma in the Era of Novel Agents: A Multicenter Retrospective Study.
    Zannetti BA; Saraceni F; Cellini C; Fabbri E; Monaco F; Guarini A; Laszlo D; Martino M; Olivieri A; Imola M; Tosi P; Chiarucci M; Zuffa E; Lanza F
    Transplant Cell Ther; 2021 Mar; 27(3):244.e1-244.e8. PubMed ID: 33781522
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improved progression-free and event-free survival in myeloma patients undergoing PBSCH receiving a cyclophosphamide + G-CSF regimen than G-CSF alone.
    Tanimura A; Hirai R; Nakamura M; Takeshita M; Hagiwara S; Miwa A
    Int J Hematol; 2018 May; 107(5):559-567. PubMed ID: 29388164
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of engraftment following different stem cell mobilization modalities in patients with multiple myeloma treated with a uniform induction regimen containing bortezomib, cyclophosphamide and dexamethasone.
    Benyamini N; Avivi I; Dann EJ; Zuckerman T; Lavi N; Katz T
    Ann Hematol; 2017 Mar; 96(3):461-467. PubMed ID: 28013359
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Comparison of etoposide combined with G-CSF and cyclophosphamide combined with G-CSF in the mobilization of autologous peripheral blood stem cells in patients with multiple myeloma].
    Wang GR; Yang GZ; Geng CY; Leng Y; Wu Y; Liu AJ; Chen WM
    Zhonghua Xue Ye Xue Za Zhi; 2024 Apr; 45(4):351-356. PubMed ID: 38951062
    [No Abstract]   [Full Text] [Related]  

  • 26. Single-dose etoposide is an effective and safe protocol for stem cell mobilization in patients with multiple myeloma.
    Park Y; Kim DS; Jeon MJ; Lee BH; Yu ES; Kang KW; Lee SR; Sung HJ; Nam MH; Yoon SY; Choi CW; Kang ES; Cho D; Kim K; Kim BS; Kim DW; Kim SJ
    J Clin Apher; 2019 Oct; 34(5):579-588. PubMed ID: 31283042
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of biosimilar granulocyte colony-stimulating factor versus originator granulocyte colony-stimulating factor in peripheral blood stem cell mobilization in de novo multiple myeloma patients.
    Martino M; Recchia AG; Moscato T; Fedele R; Neri S; Gentile M; Alati C; Vincelli ID; Piro E; Penna G; Musolino C; Ronco F; Molica S; Morabito F
    Cytotherapy; 2015 Oct; 17(10):1485-93. PubMed ID: 26188967
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Peripheral blood progenitor cell mobilization with intermediate-dose cyclophosphamide, sequential granulocyte-macrophage-colony-stimulating factor and granulocyte-colony-stimulating factor, and scheduled commencement of leukapheresis in 225 patients undergoing autologous transplantation.
    Bashey A; Donohue M; Liu L; Medina B; Corringham S; Ihasz A; Carrier E; Castro JE; Holman PR; Xu R; Law P; Ball ED; Lane TA
    Transfusion; 2007 Nov; 47(11):2153-60. PubMed ID: 17958545
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of two dose levels of cyclophosphamide for successful stem cell mobilization in myeloma patients.
    Winkelmann N; Desole M; Hilgendorf I; Ernst T; Sayer HG; Kunert C; Mügge LO; Hochhaus A; Scholl S
    J Cancer Res Clin Oncol; 2016 Dec; 142(12):2603-2610. PubMed ID: 27640002
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stem cell collection in patients with multiple myeloma: impact of induction therapy and mobilization regimen.
    Nazha A; Cook R; Vogl DT; Mangan PA; Gardler M; Hummel K; Cunningham K; Luger SM; Porter DL; Schuster S; O'Doherty U; Siegel D; Stadtmauer EA
    Bone Marrow Transplant; 2011 Jan; 46(1):59-63. PubMed ID: 20421869
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of stem cell mobilization regimen on lymphocyte collection yield in patients with multiple myeloma.
    Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP
    Cytotherapy; 2008; 10(5):507-17. PubMed ID: 18608354
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low-dose or intermediate-dose cyclophosphamide plus granulocyte colony-stimulating factor for progenitor cell mobilisation in patients with multiple myeloma.
    Jantunen E; Putkonen M; Nousiainen T; Pelliniemi TT; Mahlamäki E; Remes K
    Bone Marrow Transplant; 2003 Mar; 31(5):347-51. PubMed ID: 12634725
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Selection of a mobilization regimen for multiple myeloma based on the response to induction therapy: granulocyte-colony stimulating factor (G-CSF) alone versus high-dose cyclophosphamide plus G-CSF.
    Jang JE; Cheong JW; Kim SJ; Cho H; Suh C; Lee H; Eom HS; Yhim HY; Lee WS; Min CK; Lee JH; Park JS; Kim JS
    Leuk Lymphoma; 2016; 57(6):1389-97. PubMed ID: 26428939
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: high-dose cyclophosphamide plus GM-CSF vs G-CSF alone.
    Alegre A; Tomás JF; Martínez-Chamorro C; Gil-Fernández JJ; Fernández-Villalta MJ; Arranz R; Díaz MA; Granda A; Bernardo MR; Escudero A; López-Lorenzo JL; Fernández-Rañada JM
    Bone Marrow Transplant; 1997 Aug; 20(3):211-7. PubMed ID: 9257889
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cyclophosphamide-based stem cell mobilization in relapsed multiple myeloma patients: A subgroup analysis from the phase III trial ReLApsE.
    Baertsch MA; Schlenzka J; Lisenko K; Krzykalla J; Becker N; Weisel K; Noppeney R; Martin H; Lindemann HW; Haenel M; Nogai A; Scheid C; Salwender H; Fenk R; Graeven U; Reimer P; Schmidt-Hieber M; Goerner M; Schmidt-Wolf IGH; Klein S; Ho AD; Goldschmidt H; Wuchter P
    Eur J Haematol; 2017 Jul; 99(1):42-50. PubMed ID: 28370401
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimal chemo-mobilization for the collection of peripheral blood stem cells in patients with multiple myeloma.
    Song GY; Jung SH; Ahn SY; Jung SY; Yang DH; Ahn JS; Kim HJ; Lee JJ
    BMC Cancer; 2019 Jan; 19(1):59. PubMed ID: 30642286
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plerixafor: A chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's lymphoma or multiple myeloma.
    Steinberg M; Silva M
    Clin Ther; 2010 May; 32(5):821-43. PubMed ID: 20685493
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Peripheral blood CD34+ cell monitoring after cyclophosphamide and granulocyte-colony-stimulating factor: an algorithm for the pre-emptive use of plerixafor.
    Farina L; Spina F; Guidetti A; Longoni P; Ravagnani F; Dodero A; Montefusco V; Carlo-Stella C; Corradini P
    Leuk Lymphoma; 2014 Feb; 55(2):331-6. PubMed ID: 23656194
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intermediate-dose cytarabine plus G-CSF as mobilization regimen for newly diagnosed multiple myeloma and heavily pre-treated patients with hematological and non-hematological malignancies.
    Callera AF; Rosa ES; Callera F
    Transfus Apher Sci; 2019 Jun; 58(3):318-322. PubMed ID: 30961974
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Growth factor and patient-adapted use of plerixafor is superior to CY and growth factor for autologous hematopoietic stem cells mobilization.
    Costa LJ; Miller AN; Alexander ET; Hogan KR; Shabbir M; Schaub C; Stuart RK
    Bone Marrow Transplant; 2011 Apr; 46(4):523-8. PubMed ID: 20622909
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.